---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-24-011545"
form_type: "8-K"
ticker: "CLNN"
cik: "0001822791"
company_name: "Clene Inc."
filed_at: "2024-04-09T23:59:59+00:00"
generated_at: "2026-06-04T01:05:13.288694+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Clene enters $7.3M subaward with Columbia University for NIH-funded ALS Expanded Access Program

## Summary
- Clene Nanomedicine signed subaward for up to $7.3M for initial phase of NIH grant supporting CNM-Au8 EAP in ALS.
- Total subaward potential under $45.1M NIH grant could reach $30.9M through August 2027.
- Funds reimburse expenses from Sept 25, 2023 to Aug 31, 2024; invoiced monthly or quarterly.
- Agreement protects Clene's background IP; no license granted to Columbia or US Government.
- Either party may terminate with 30 days' notice; termination required if NIH terminates grant.

## SEC filing metadata
- accession: 0001437749-24-011545
- form_type: 8-K
- ticker: CLNN
- cik: 0001822791
- company_name: Clene Inc.
- filed_at: 2024-04-09T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 1.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1822791/000143774924011545/0001437749-24-011545-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1822791/000143774924011545/clnn20240409_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-24-011545
- JSON: https://secwatch.observer/filing/0001437749-24-011545.json
- Plain text: https://secwatch.observer/filing/0001437749-24-011545.txt

## Key facts
- Material Agreements
  Clene Inc. entered into Subaward with Colombia University valued at up to $7.3 million (effective 2024-04-03).
  - Action: entry
  - Counterparty: Colombia University
  - Value: up to $7.3 million
  - Effective: 2024-04-03
  source text: On April 3, 2024, the Company entered into a grant subaward agreement (the “Subaward”) with Colombia pursuant to the NIH Grant.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1822791/000143774924011545/0001437749-24-011545-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.